Announcements Trials
Browse Landscape

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Other 1

Conditions

Obesity 3Breast Neoplasms 3Prostatic Neoplasms 2Overweight 2Melanoma 2Substance Withdrawal Syndrome 1Skin Neoplasms 1Metabolic Syndrome 1Kidney Neoplasms 1Inflammation 1Glioma 1Glioblastoma 1Dyslipidemias 1Chronic Pain 1Carcinoma, Lobular 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Electrocardiography 2semaglutide 1bupropion hydrochloride, naltrexone hydrochoride drug combination 1Topiramate 1Tirzepatide 1Surveys and Questionnaires 1Qsymia 1Pulse Wave Analysis 1Phlebotomy 1Phentermine 1Naltrexone 1Metformin 1Magnesium 1Liraglutide 1Glucagon-Like Peptide-1 Receptor 1Exercise Test 1Educational Status 1Echocardiography 1Diethylpropion 1Carnitine 1Bupropion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Dyslipidemias × Naltrexone × Clear all
NCT05756764 2025-09-09

Anti-obesity Pharmacotherapy and Inflammation

Louisiana State University Health Sciences Center in New Orleans

Active not recruiting
30 enrolled
Other

Inflammation, Obesity, Metabolic Syndrome, Dyslipidemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡